1. Home
  2. TENX vs VRCA Comparison

TENX vs VRCA Comparison

Compare TENX & VRCA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Tenax Therapeutics Inc.

TENX

Tenax Therapeutics Inc.

N/A

Current Price

$1.48

Market Cap

73.8M

Sector

Health Care

ML Signal

N/A

Logo Verrica Pharmaceuticals Inc.

VRCA

Verrica Pharmaceuticals Inc.

N/A

Current Price

$3.31

Market Cap

88.0M

Sector

Health Care

ML Signal

N/A

Company Overview

Basic Information
Metric
TENX
VRCA
Founded
1967
2013
Country
United States
United States
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
73.8M
88.0M
IPO Year
2001
2018

Fundamental Metrics

Financial Performance
Metric
TENX
VRCA
Price
$1.48
$3.31
Analyst Decision
Buy
Strong Buy
Analyst Count
10
5
Target Price
$10.29
★ $13.67
AVG Volume (30 Days)
★ 1.4M
50.8K
Earning Date
11-05-2026
11-12-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
★ N/A
EPS
★ N/A
N/A
Revenue
N/A
★ $35,577,000.00
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
$54.67
P/E Ratio
N/A
★ N/A
Revenue Growth
N/A
★ 370.22
52 Week Low
$1.31
$3.08
52 Week High
$19.40
$9.82

Technical Indicators

Market Signals
Indicator
TENX
VRCA
Relative Strength Index (RSI) 35.62 47.48
Support Level $1.34 $3.19
Resistance Level $2.01 $5.94
Average True Range (ATR) 0.12 0.34
MACD 0.00 0.05
Stochastic Oscillator 6.25 38.94

Price Performance

Historical Comparison
TENX
VRCA

About TENX Tenax Therapeutics Inc.

Tenax Therapeutics Inc is a phase three, development-stage pharmaceutical company focused on identifying and developing therapeutics that address cardiovascular and pulmonary diseases with high unmet medical need, with an initial therapeutic focus on pulmonary hypertension. Its drug development pipeline comprises: Levosimendan, a novel, first-in-class K-ATP activator and calcium sensitizer developed for intravenous use in hospitalized patients with acutely decompensated heart failure; and Imatinib, as a potential therapy for pulmonary arterial hypertension. The company is currently conducting clinical trials only for levosimendan as its prioritized product candidate to evaluate its potential to help patients with pulmonary hypertension.

About VRCA Verrica Pharmaceuticals Inc.

Verrica Pharmaceuticals Inc is a therapeutics company developing and commercializing medications for the treatment of dermatologic diseases, including skin cancers. Its commercial product and portfolio of product candidates are clinician administered therapies in areas of high unmet need. This product portfolio consists of one product with an approved indication for molluscum contagiosum, or molluscum, with the potential for several follow-on indications, as well as additional pipeline product candidates. Its commercial product, YCANTH (VP-102), for the treatment of molluscum in adult and pediatric patients two years of age and older. YCANTH (VP-102) is a proprietary drug-device combination that contains a GMP-controlled formulation of cantharidin.

Share on Social Networks: